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What’s known on the subject? and What does the study add?
 
Nocturia is currently defined by the International Continence Society (ICS) as the complaint 
that an individual has to wake at night one or more times to void. It is, however, an 
underreported, understudied, and infrequently recognized problem in adults. Many factors 
may contribute to nocturia which are treatable, yet patients do not seek care or the 
condition may not be identified by providers.
This paper aims to help healthcare providers better serve patients who are experiencing 
nocturia by summarizing current research, clinical approaches, and treatment options. 
The results of the conference provide a balanced evaluation of the full treatment 
armamentarium capable of meeting the needs of patients with the manifold causes of 
nocturia such as nocturnal polyuria, overactive bladder, or benign prostatic hyperplasia.
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INTRODUCTION
 
Nocturia is currently defined by the ICS as the complaint that an individual has to wake at 
night one or more times to void [1]. Evidence suggests that most people with 
 
<
 
2 voids/night 
generally have only minimal bother from the condition. Only when 
 
≥
 
2 voids/night occurs on 
a regular basis is nocturia likely to have more serious consequences for the patient [2]. For 
example, patients with LUTS, which encompass voiding, post-voiding, and storage symptoms 
(including nocturia), report that nocturia of 
 
≥
 
2 voids/night is one of their most bothersome 
symptoms. A recent population-based study of LUTs in Finland suggested that moderate or 
major bother are only reported by those with 
 
≥
 
3 voids/night [3].
Nocturia is an underreported, understudied, 
and infrequently recognised problem in adults 
[4]. Many factors can contribute to nocturia, 
which may be part of the reason this 
condition has been largely overlooked or 
considered only as a symptom of some other 
disorder. However, nocturia can legitimately 
be considered a clinical entity in its own 
right that requires careful diagnostic 
evaluation.
Nocturia may exact a range of detrimental 
effects because of the associated sleep 
fragmentation experienced by patients on a 
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regular basis. These effects include: reduced 
health-related quality of life (HRQL), mood 
disturbance, reduced productivity at work, 
poorer overall health, and increased falls and 
fractures [5,6]. Some studies suggest that the 
degree of bother associated with nocturia is 
significantly related to sleep status and 
attendant deficits rather than nocturnal 
voiding frequency per se [7]. However, despite 
these effects many people with nocturia do 
not seek help from a healthcare provider [8]. 
Patients may not recognise nocturia as a 
medical condition amenable to treatment. 
They may simply view it as an unavoidable 
aspect of ageing, or may be embarrassed or 
reluctant to discuss symptoms involving 
urination.
This consensus opinion paper aims to help 
physicians and other healthcare providers 
better serve patients with nocturia by 
summarizing current research, clinical 
approaches, and treatment options.
 
METHODS
 
In April, 2010, an interdisciplinary conference 
on nocturia was convened by the New 
England Research Institutes, Inc. (NERI), in 
Cambridge, MA, USA. The goal of the 2-day 
conference was to generate a consensus on 
the current state and direction of the field of 
nocturia as it pertains to clinical decision-
making for primary care providers, urologists, 
and other health professionals. Nine panellists 
were selected on the basis of research or 
clinical expertise in nocturia or nocturia-
related symptoms, as well as their position as 
‘thought leaders’ in this field. The panellists 
represented a wide range of disciplinary 
backgrounds, including urology, 
urogynaecology, psychometrics, and sleep 
physiology. Full attendance at the conference 
was required.
Panellists presented prepared findings on the 
first day of the conference. Every member of 
the panel received equal time to present and 
to respond to questions from other panel 
members. All panel members were required to 
submit their presentations before the meeting 
for scrutinising by representatives of the 
Boston University School of Medicine 
Department of Continuing Medical Education 
(BU CME) to assure that the materials and 
conference met standards set forth by the 
Accreditation Council for Continuing Medical 
Education. The meeting itself was not CME 
accredited, but the NERI conference 
organizers felt it was important to enlist an 
independent entity to review all materials for 
bias and balance before the conference, as 
well as having a BU CME representative 
present during the conference.
On the second day of the conference, 
panellists discussed each of the subject areas 
presented the previous day until a consensus 
was reached and articulated. Panellists 
reviewed all key 
clinical studies 
relevant to each 
area, familiarity with 
the literature, and 
personal clinical 
experience. A summary of findings from the 
conference was provided to all panel 
members for review and approval after the 
conference, and these findings provided the 
basis for the collaborative writing of this 
paper.
 
RESULTS
Epidemiology of nocturia
 
Nocturia is most commonly thought of as a 
problem affecting older men. However, 
evidence strongly suggests that nocturia 
affects a large proportion of adults of both 
genders and in all age ranges. A recent meta-
analysis of 43 articles relevant to nocturia 
prevalence concluded that nocturia is 
common across diverse populations [9]. It is 
most prevalent in older people, but also 
affects a significant proportion of younger 
individuals. using the more clinically relevant 
criterion of 
 
≥
 
2 voids/night, this analysis found 
the following prevalence rate ranges:
• Men aged 20–40 years: 2–17%
• Women aged 20–40 years: 4–18%
• Men aged 
 
>
 
70 years: 29–59%
• Women aged 
 
>
 
70 years: 28–62%
Burgio 
 
et al
 
. [10] reported an overall 
prevalence of 58.5% among older adults, with 
a greater proportion of men (63.2%) than 
women (53.8%) having 
 
≥
 
2 voids/night. In 
general, samples considering all adults or only 
younger adults have shown a higher 
prevalence of nocturia in women [11], 
whereas samples of older adults typically 
show a higher prevalence among older men 
[12]. This is possibly due to the influence of 
bph, which is a risk factor for nocturia 
that rises significantly with age among men 
but is not a relevant factor for nocturia in 
women.
Burgio 
 
et al
 
. [10] also reported a higher 
prevalence of nocturia in both male and 
female african-americans. This finding 
corroborates an earlier report from the boston 
area community health (bach) study, which 
found that african-americans had a nearly 
90% greater odds of reporting nocturia than 
whites, even after controlling for socio-
demographic factors [13]. Further research to 
elucidate the reasons for these disparities 
 
‘Nocturia is most commonly thought of  as a 
problem affecting older men’
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remains to be conducted. Possible 
explanations include: the higher prevalence 
among african-americans of conditions 
associated with nocturia (diabetes mellitus, 
hypertension, obesity, and cardiovascular 
disease); factors not measured in existing 
studies, e.g. Rates of sleep apnoea (higher 
among african-americans); or the influence of 
sickle-cell trait (which can cause renal 
deficits) [2,9,10].
 
Predictors and risk factors: nocturia is a 
multifactorial condition
 
Nocturia has many possible contributing 
causative factors, attention to which may be 
relevant to achieve a clinically meaningful 
reduction in night-time voids. While an 
association between these risk factors and 
nocturia has been established, estimates of 
the proportion of patients with nocturia who 
are in fact affected by each underlying factor 
are not well-established. In addition, the 
causal direction between nocturia and some 
of these factors can point either way. For 
example, the risk of nocturia may be higher 
among individuals who are depressed, yet 
depression may be initiated or exacerbated by 
the sleep disruption that accompanies 
nocturia. Potential causes of nocturia can be 
categorized as arising from: bladder storage 
problems; nocturnal polyuria (NP); 24-h 
(global) polyuria; and sleep disturbance 
(Table 1) [14,15].
Although the range of possible causative 
factors in nocturia is large and often 
overlapping, some are more common than 
others. A recent population/questionnaire-
based survey of 
nocturia found that 
the most common 
predictive factors of 
nocturia in men 
were: urgency of 
urination; BPH; and 
sleep disruption (as 
manifested by snoring) [16]. In women, 
urgency, obesity, and snoring were predictive. 
Other associations included: history of 
prostate cancer and antidepressant use in 
men, and coronary artery disease and diabetes 
in women.
In a multi-institutional study NP was the most 
important contributor to nocturia [17]. As 
with other components of LUTS, there appears 
to be some longitudinal variability associated 
with nocturia with 
 
≈
 
10% of women reported 
to have spontaneous improvement or 
resolution of bothersome nocturia [18].
Obesity is a common co-morbidity in western 
society and has been implicated with the 
entire spectrum of LUTS, including nocturia. 
Asplund [19] assessed 10 216 older subjects in 
Sweden and found that nocturia events 
increased in parallel with body mass index. 
Additionally, night-time food ingestion with 
corresponding decreases in diurnal calorific 
ingestion was associated with increasing 
nocturic frequency. The author concluded 
that nocturnal frequency actually might 
contribute to an increasing risk of 
obesity.
Incorrect arginine vasopressin (AVP) levels 
have also been implicated in NP. NP 
syndrome, associated with decreased or 
undetectable levels of AVP, is characterized by 
increased night-time urinary output. This 
syndrome is especially prevalent in the elderly, 
perhaps approaching 4% [20]. Depressed AVP 
levels may be due to either a primary pituitary 
disorder or a physiological response to 
increased return of free water into the 
circulation associated with resolution of 
lower extremity third-space fluid upon 
achieving the recumbent position during 
sleep.
To better appreciate the deleterious effects of 
nocturia, it is important to understand the 
effects of disrupted sleep. Restrictions in total 
sleep time correlate with increased daytime 
fatigue and decreased daytime alertness, both 
of which may pose risks, e.g. falls, depressed 
mood, cognitive impairment, and decreased 
HRQL, outcomes that are particularly salient 
for older adults. Because nocturia routinely 
disrupts the nocturnal period and has been 
associated with relatively poor quality sleep, it 
is likely to affect sleep architecture and may 
effect waking daytime functioning.
Inadequate sleep duration, as may accompany 
nocturia, is also associated with increased 
mortality [21], as well as morbidities such 
as hypertension, obesity, and glucose 
intolerance [22]. Population-based data 
suggest that although insomnia is related 
to factors such as physical pain and 
depressed mood, nocturia represents an 
independent risk factor for compromised 
sleep quality [23].
Such observational data are consistent with 
the outcomes from experimental studies of 
 
‘Although the range of  possible causative factors 
in nocturia is large and often overlapping, some 
are more common than others’
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healthy younger and middle-aged people 
who have been temporarily deprived of 
sleep, either partially or totally. These studies 
have consistently found a range of deficits 
arising from disrupted sleep, including: 
[24–26]
• Reduced glucose tolerance
• Reduced thyrotrophin concentrations
• Raised evening cortisol concentrations
• Greater sympathetic nervous system 
activity
• Decreased plasma levels of leptin and 
concomitant increases in plasma levels of 
ghrelin (which may skew appetite regulation 
and promote obesity)
In addition to the adverse effects of reduced 
sleep durations, nocturia may be associated 
with sleep apnoea. Community-based elderly 
populations who have higher levels of sleep 
disordered breathing (
 
>
 
25 breathing events/
h), have nearly double the number of nocturia 
episodes compared with those with low rates 
of sleep apnoea [27]. Nocturia episodes in 
these individuals can be at least partially 
ameliorated by continuous positive airway 
pressure treatment for sleep apnoea [28].
 
Impact on HRQL and overall health
 
Nocturia affects multiple domains of health, 
especially for older persons. These domains 
include HRQL, healthcare costs, increased 
morbidity, missed diagnoses, and 
inappropriate treatment.
Nocturia carries a high burden of personal 
distress, discomfort, and even disability. 
Among men, nocturia is the ‘most 
bothersome’ LUT [29]. Affected persons 
describe their nocturia as ‘debilitating, 
frustrating, distressing, and puzzling’, 
 
TABLE 1 
 
Potential causes or associated risk factors for nocturia [88,89]
 
Bladder storage problems • Reduced functional bladder capacity (i.e. extrinsic compression from uterine fibroids, urogenital prolapse, ovarian tumour)
• Bladder pain syndrome
• BOO (i.e. BPH, BPO)
• Nocturnal DO
• Neurogenic bladder
• Cancer of bladder, prostate, or urethra
• Learned voiding dysfunction
• Bladder or ureteric calculi
• DO (idiopathic or neurogenic)
• OAB
• Voiding problems and postvoid residual urine (i.e. uterine fibroids, urogenital prolapse, urethral stricture, detrusor failure)
• Urogenital ageing (i.e. atrophy caused by oestrogen deficiency)
NP • Congestive heart failure
• Obstructive sleep apnoea
• Peripheral oedema (i.e. venous stasis, hepatic failure)
• Excessive evening fluid intake
• Circadian defect in secretion or action of AVP
24-h polyuria • Diabetes mellitus
• Diabetes insipidus
• Primary polydipsia
Sleep disturbance Primary sleep disorders
• Insomnia
• Sleep apnoea
• Periodic leg movements
• Narcolepsy
• Arousal disorders (i.e. sleepwalking, nightmares)
Other potential factors Medical disorders
• Cardiac failure
• Chronic obstructive pulmonary disease
• Endocrine disorders
Neurological conditions
• Parkinson disease
• Dementia
• Epilepsy
Psychiatric conditions
• Depression
• Anxiety
Chronic pain disorders
Alcohol or drug use (consumption or withdrawal)
Medications (i.e. corticosteroids, diuretics, 
 
β
 
-adrenergic antagonists)
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particularly in its perceived unpredictability 
[2]. Older persons experience a diminished 
self-image, feel prematurely ‘old’, and worry 
about nocturia causing night-time falls [30]. 
Bother from nocturia is related to the 
frequency of episodes; in a population-based 
study, any degree of bother was associated 
with 
 
≥
 
2 voids/night, and moderate-to-severe 
bother with 
 
≥
 
3 voids/night [3]. Notably, in 
nearly all nocturia epidemiological and 
treatment studies, frequency is characterized 
as ‘episodes per night’ without consideration 
of the time a person spends in bed. The impact 
and burden of 3 voids/night is likely to be 
greater in persons who typically sleep for 6 h 
vs those who sleep for 
 
≥
 
8 h. Nocturia also 
has significant effects on the bed-partners 
and caregivers of affected older persons. This 
may ultimately lead to sleeping in separate 
beds, which can have powerful symbolic 
significance within a relationship. Caregivers 
of patients with dementia and nocturia have 
significantly higher rates of depression and 
chronic illness [31].
The fear of falling experienced by many older 
persons with nocturia is well-founded: most 
night-time falls are associated with bathroom 
trips, vs only 20% of daytime falls [32]. 
Nocturia increases the risk of an incident fall 
25% over 3 years 
[33]. Fall risk 
increases with 
nocturia frequency; 
the odds ratio (OR) 
for a fall increases 
from 1.84 with 2 voids/night, to 2.15 with 3 
voids/night [23]. Significantly, nocturia is 
associated with injurious falls, and greater risk 
is associated with higher nocturia frequency. 
The OR for a hip fracture is 1.36 in older men 
having 
 
≥
 
2 voids/night, and 1.80 having 
 
≥
 
3 
voids/night [34].
Nocturia may be the herald symptom of 
significant underlying medical conditions and 
problems, which, if overlooked, can result in 
significant morbidity and even mortality. 
Patients may report nocturia more than other 
symptoms of an underlying condition because 
of its bothersome nature, a ‘window of 
opportunity’ to identify other conditions. 
Therefore, the complaint of nocturia should 
prompt not only an evaluation of its possible 
medical causes, but also screening and 
evaluation of the patient for previously 
unrecognized comorbidity. Medical causes 
of nocturia to consider include not only 
cardiovascular disease and sleep apnoea, but 
also moderate alcohol consumption, restless 
leg syndrome, poor night-time glycaemic 
control in persons with diabetes, and other 
causes of primary sleep disturbance (e.g. pain 
and Parkinson disease).
Failure to consider the medical causes of 
nocturia can also lead to treatments that have 
scant evidence for efficacy and/or associated 
risks (see relevant sections on 
pharmacological treatment later in this 
article). Misdirected pharmacological therapy 
also increases the chance of polypharmacy. 
Over 40% of older men and 57% of women 
already take five or more medications, and 
 
≈
 
11% of all older persons take 10 or more; 
moreover, up to 25% of medications taken by 
older persons may be inappropriate [35]. 
Polypharmacy results in higher risk of adverse 
reactions and drug interactions, as well as 
decreased adherence and higher healthcare 
costs.
 
Economic impact
 
Moderate-to-severe nocturia is associated 
with significant increases in healthcare costs. 
Among persons with 
 
≥
 
3 voids/night, nocturia 
is associated with higher total medical costs, 
greater number of hospitalization days, higher 
inpatient medical costs, and higher outpatient 
medical costs [36]. Such costs are not limited 
to older adults.
As noted earlier, 15–20% of young adults 
report 
 
≥
 
2 voids/night. Some evidence 
suggests that younger workers, specifically, 
may experience more troubled sleep and 
associated problems than older adults [37]. 
Whether caused by, or simply exacerbated by, 
nocturia, these sleep interruptions may erode 
the general state of health and well-being. 
These negative effects of nocturia may be 
particularly difficult for younger patients 
because they are more likely to have active 
lifestyles and demanding work schedules. As 
younger adults are more commonly engaged 
in the workforce than older adults, nocturia 
can be expected to exert a disruptive 
economic impact disproportional to the 
prevalence of this condition relative to that of 
older adults.
The impact of nocturia on work productivity 
was recently estimated using prevalence data 
from the BACH Study and data from the USA 
Bureau of Labor Statistics [38]. Subjects 
reporting nocturia had greater impairment in 
productivity as measured by the Work 
 
‘Moderate-to-severe nocturia is associated with 
significant increases in healthcare costs’
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Productivity and Activity Impairment 
questionnaire (14% vs 5%; 0% maximum 
productivity, 100% total loss of work 
productivity). The study concluded that the 
annual cost to the USA society resulting from 
loss of productivity from nocturia in the 
population aged 
 
<
 
65 years is 
 
≈
 
$61 billion/
year, and $1.5 billion/year for people aged 
 
≥
 
65 years due primarily to the cost of treating 
complications of falls in older adults.
 
CLINICAL ASPECTS
Evaluation of patients with nocturia
 
Although nocturia is common in the general 
population and may be bothersome or even 
distressing to patients, it may not be the 
initial complaint of patients. Clinicians need 
to be alert to the possibility that their patients 
are affected by nocturia but may be reluctant 
to discuss it. Asking patients about nocturia, 
and LUTS in general, may help them talk more 
openly about symptoms related to night-time 
voiding and to what degree they are bothered 
about it. Given the multi-factorial nature of 
nocturia, initial assessment involves taking a 
thorough history to more clearly understand 
the patient’s symptoms. Questionnaires are 
useful in quantifying the effect of nocturia on 
daily functioning [39,40]. Patients should be 
evaluated for underlying disease states, 
cardiovascular conditions, and consumption 
of liquids (including, specifically, those 
containing alcohol and caffeine). Urine 
analysis, urine culture, and cytology should 
also be carried out; abnormalities in any 
of these should be further evaluated with 
cystoscopy or urography where clinically 
appropriate.
An important causative factor in nocturia 
may be NP, typically defined as a nocturnal 
urinary output 
 
>
 
20% of the daily total in 
young adults and 
 
>
 
33% in older adults. NP is 
present in up to 83% of the general 
population with nocturia and, as such, 
clinicians should be alert to the fact that this 
overproduction of urine at night may be a key 
contributory factor in their patients, even 
among those with an overactive bladder 
(OAB) or benign prostatic obstruction (BPO) 
diagnosis [41]. NP is often missed during 
the evaluation and diagnosis of nocturia, 
which may interfere with a clinically 
significant improvement in nocturia for 
these patients.
A key tool in the evaluation and diagnosis of 
nocturia is the frequency-volume chart (FVC), 
in which patients record the volume and 
timing of daytime and night-time voids for 1–
3 days. The voiding patterns revealed by FVC 
data can provide clinicians with invaluable 
guidance regarding aetiology and treatment 
(Table 2). The use of FVCs is additionally 
recommended because of demonstrated 
discrepancies between nocturnal voiding 
data obtained using FVCs and data obtained 
from subjective questionnaires such as the 
IPSS [43].
The multifactorial nature of nocturia suggests 
that for many patients, nocturia treatment 
may involve multiple incremental therapeutic 
manoeuvres to obtain a clinically meaningful 
benefit [16].
 
Nocturia and OAB
 
Nocturia is often confused with LUTS and 
assumed to be a symptom of OAB or BPO. Not 
all patients with OAB or BPO have nocturia 
and the relationship between nocturia and 
OAB is not well understood. There are several 
reasons for this that relate to the definition of 
both conditions. Firstly, for nocturia, there are 
no validated nocturia instruments that 
determine:
1) why the patient was awakened,
2) why he or she voided (i.e. out of 
convenience, habit, urge, or urgency), and
3) whether the patient fell back asleep.
Secondly, the definitions of urgency (the 
 
sine-qua-non
 
 symptom of OAB) and OAB 
itself are the subject of debate. For example, 
using very strict criteria for OAB, Tikkinen [44] 
found a prevalence of only 
 
≈
 
8% compared 
with the oft-quoted 16–17%.Thirdly the 
symptoms of OAB have a wide differential 
diagnosis that must be considered.
Nonetheless, clear associations between OAB 
and nocturia exist. In a Finnish population-
based study of 6000 participants, Tikkinen 
[44] reported that 17% of patients with 
nocturia reported OAB. Conversely, 80% 
of patients with OAB reported nocturia. 
Furthermore, there was a direct relationship 
between the number of nocturnal voids and 
the prevalence of OAB (
 
P
 
 
 
<
 
 0.001). Nocturia 
and OAB increased with age (
 
P
 
 
 
<
 
 0.001) 
and this relationship persisted across age 
groups.
In an earlier study, Tikkinen 
 
et al
 
. [16] reported 
an incidence of OAB in 8% and 9% of men 
and women respectively using the symptom 
urgency as the marker of OAB. These data 
suggest that OAB is no more common in 
patients with nocturia than in the general 
population. In contrast, several authors have 
reported an incidence of OAB as high as 33% 
in patients with nocturia and, conversely a 
50% incidence of nocturia in those with OAB 
[45–47].
In an observational study of women with 
OAB who underwent urodynamics, Matharu 
 
et al
 
. [48] reported that in women aged 
 
>
 
40 years, the incidence of detrusor 
overactivity (DO) increased with increasing 
self-reported nocturia; i.e., the more 
night-time voids, the greater the chances 
of having DO.
Indirect evidence that OAB plays a 
relatively minor role in the genesis of 
nocturnal voids comes from studies 
showing that OAB medications are not 
effective in reducing night-time voids 
[49,50]. Although, these studies do suggest 
that antimuscarinics reduce the number 
of night-time voids that are due to urgency. 
For example, Brubaker and Fitzgerald [49], 
reported that solifenacin reduced nocturnal 
voids by 36% in patients without NP, 
while having no effect on overall nocturnal 
voids.
From the studies cited above, we can conclude 
that:
 
TABLE 2 
 
Based upon analysis of the 24-h FVC, the patient may have
 
Reduced voided volume (indicating a reduced capacity of the bladder to store urine) either globally or 
exclusively during the hours of sleep (low nocturnal bladder capacity).
Excessive urine production during the day and night (polyuria, where 24 h urine volume is 
 
>
 
40 mL/kg 
[42])
Excessive urine production specifically at night where 24 h urine output remains normal (NP, see above)
Combinations of the above (‘mixed aetiology’)
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1) most patients with nocturia do not have 
OAB,
2) most patients with OAB do have nocturia,
3) antimuscarinics do not appear to be 
efficacious for nocturia, and
4) antimuscarinics may be effective for 
nocturnal voids due to urgency.
Ultimately, to evaluate the relationship 
between nocturia and OAB better methods 
are needed to determine whether the patient 
was awakened by an urge to void or by 
something else, and why he or she voids once 
awakened. Thus, a clearer means of 
distinguishing urgency from a normal urge to 
void and a broader definition of OAB is 
needed. The Standardisation Committee of 
ICS states that: ‘(Urinary) urgency, with or 
without urge incontinence, usually with 
frequency and nocturia, can be described 
as the overactive bladder syndrome.if there 
is no proven infection or other obvious 
pathology’ [51]. Urgency is defined as ‘. 
the complaint of a sudden compelling 
desire to pass urine, which is difficult to 
defer’. However, these definitions may be 
too restrictive, especially insofar as 
determining the relationship between 
OAB and nocturia.
In a study designed to define the sensation of 
urgency, patients were asked to describe, in 
their own words, what they meant by urgency 
[52]. The most 
common answer 
was, ‘If I 
wait too long, I have 
trouble getting to 
the bathroom in 
time’. In fact, only a few patients described 
urgency as a ‘sudden’ event. Based on these 
data, two distinct types of urgency emerged 
that may have relevance for determining why 
a patient voids when awakened from sleep. 
Type 1 urge was described as an 
intensification of the normal urge to void and 
occurred in 69% of patients with OAB, and 
type 2 (31%) was a sudden precipitous urge 
that is a different sensation from the normal 
urge, which conformed 
to the ICS definition. In patients with 
type 1 urge, the intensity of the urge to 
void increases over time and culminates in 
micturition; whereas, in type 2 the patient has 
little or no warning and must rush to the 
bathroom. The idea that the urge to void can 
be graded runs counter to ICS doctrine, but 
nevertheless has strong scientific support 
[53–55].
Another confounding factor in the analysis of 
the relationship between OAB and nocturia is 
that the ICS definition considers OAB to be a 
syndrome, with symptoms suggestive of DO 
(involuntary contractions of the bladder), and 
recommends that the term OAB be used only 
‘if there is no proven infection or other 
obvious pathology’. This definition has 
profound effects on research methodology 
because, in fact, there are many conditions in 
the differential diagnosis of OAB symptoms 
that should, theoretically, be exclusion 
criteria. In practice though, most studies do 
not include such exclusion criteria (Fig. 1) 
[56]. In conclusion, understanding the 
relationship between nocturia and OAB 
requires considerable future research, 
involving the following steps: the 
definitions of nocturia, OAB and urgency 
need to be better defined and studies are 
needed to determine the reasons why 
patients arise from sleep to void, whether 
it is because of a bladder sensation or 
something else.
 
MANAGEMENT
Lifestyle changes and supplements
 
Most patients initially respond to nocturia by 
engaging in one or more life-style 
modifications (Table 3). These techniques 
usually enable patients to manage their 
symptoms initially. However, as nocturia 
progresses, these modifications lose their 
effectiveness and many patients then turn to 
supplements of one sort or another or 
eventually seek medical intervention.
Many patients try herbal supplements to limit 
their nocturia. Supplements are attractive 
because:
• They are perceived as ‘natural’
• They are easy to obtain (available in most 
drug stores and over the internet)
• No doctor input is needed
• They are relatively inexpensive
• They are perceived to be safe, i.e. without 
side effects (mainly because they have never 
been adequately tested)
In the USA, 50–90% of men have tried 
supplements before seeking medical 
treatment for their LUTS/BPH [57].
Several plant-based extracts are currently on 
the market as supplements purporting to 
 
‘Most patients initially respond to nocturia by 
engaging in one or more life-style modifications’
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improve symptoms of BPH/LUTS (Table 4) 
[57]. The most commonly-used supplement 
for nocturia symptoms is 
 
Serenoa repens
 
, 
saw palmetto berry extract [57]. Because 
these products are plant extracts and 
manufacturers use several different 
extraction processes, there is significant 
variability in the products being sold. For 
example, the dosage of saw palmetto berry 
extract varied from –97% to 
 
+
 
140% of the 
dose stated on the bottle label with half the 
products having 
 
<
 
 20% of the stated dose 
[58].
Numerous mechanisms of action for saw 
palmetto berry extract have been proposed. 
These theories are frequently based upon 
 
in 
vitro
 
 experiments, usually with cell cultures. 
However, none of the purported mechanisms 
of action have been confirmed [59].
The only saw palmetto product that has 
undergone extensive clinical study is 
Permixon brand saw palmetto berry extract 
(Pierre Fabre Medicament, Castres, France). 
Two meta-analyses of all the published and 
unpublished trials of Permixon have been 
undertaken [60,61]. The initial analysis 
included 13 trials with 2794 patients. The 
results showed that nocturia was decreased 
by placebo by 0.69 voids/night while the 
Permixon treated patients’ nocturia episodes 
were reduced by 1.19 voids/night. Maximum 
urinary flow rates (Q
 
max
 
) were increased 
by placebo by 0.51 mL/s and by Permixon 
by 2.71 mL/s. In that study there was a 
statistically significant improvement in Q
 
max
 
 
and reduction in nocturia greater than 
placebo, although whether these changes 
have any clinical significance is unclear 
[60]. The second meta-analysis of Permixon 
included 17 studies with 4820 patients [61]. 
As in the first analysis, nocturia was decreased 
slightly and Q
 
max
 
 improved slightly at levels 
that reached statistical, but perhaps not 
clinical, significance.
A National Institutes of Health-sponsored, 1-
year, placebo-controlled trial of 225 patients 
evaluating Sabalselect (Indena California, 
USA) brand saw palmetto berry extract 
showed no difference in the reduction of 
LUTS as measured by the AUA Symptom 
Score [62]. The reduction was 0.72 for 
placebo and 0.68 for the product. In fact, 
during the placebo run-in period, there 
was a reduction of 1.49, which was a 
greater effect than the product alone. There 
were minor but not statistically significant 
improvements in urinary flow rates and BPH 
impact Index (
 
−
 
0.33 vs 
 
−
 
0.09) with the saw 
palmetto. This trial is important because it 
was the only non-company sponsored trial in 
this area and it did not show any efficacy for 
the herbal product.
 
Non-antidiuretic pharmacotherapy
 
In critically reviewing the literature on the 
subject of non-antidiuretic pharmacotherapy 
for nocturia, a few issues immediately arise 
with implications for assessing the efficacy 
of any given treatment. A ‘successful’ 
treatment programme for nocturia should 
result in a clinically significant (as opposed to 
statistically significant) reduction in nocturnal 
awakenings to void and a subsequent positive 
effect on the negative issues associated with 
nocturia, yet limited evidence-based medicine 
exists.
Several studies have explored the efficacy of 
terazosin, finasteride, or combinations of 
these drugs in improving nocturia symptoms. 
For example, the effect of tamsulosin oral-
controlled absorption system (OCAS) 0.4 mg. 
was assessed in a phase 3B pilot study in men 
with LUTS/BPH and 
 
≥
 
2 voids/night [63]. 
That study concluded that ‘tamsulosin 
OCAS 0.4 mg was superior to placebo in 
reducing . . . the mean IPSS nocturia’. 
However, the ‘significant reduction’, 
amounted to a mean change of 3.1 to 2.3 
awakenings for placebo and 3.1 to 2.0 for 
drug. The change in the time to the first 
awakening to void was not statistically 
significant. Another representative study 
was a secondary analysis of IPSS nocturia 
data from the Veterans’ Administration 
Cooperative Study [64]. The data from 1078 
 
FIG. 1.
 
OAB was found to be idiopathic
in only 5% of men. The
following differential
diagnoses were reported.
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TABLE 3 
 
Life-style modifications to manage nocturia
 
Pre-emptive voiding
Nocturnal dehydration
Dietary and fluid restrictions (avoidance of caffeinated beverages, alcohol etc.)
Medication timing (diuretics in the mid-afternoon)
Evening leg elevation to mobilize fluids
Use of sleep medications/aides
Use of protective undergarments
 
TABLE 4 
 
Plant extracts used as 
supplements for BPH/LUTS 
[57]
 
Latin name Common name
 
Serenoa repens, Sabal serrulata
 
American dwarf palm/saw 
palmetto berry
 
Pygeum africanum
 
African plum tree
 
Hypoxi rooperi
 
South African star grass
 
Urtica dioica
 
Stinging nettle
 
Secale cerale
 
Rye pollen
 
Cucurbita pepo
 
Pumpkin seed
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men, aged 45–80 years, with a diagnosis of 
BPH who completed 12 months of the trial 
were analysed specifically for reduction 
in nocturia. There were four arms in the 
study: terazosin, finasteride, combined 
terazosin plus finasteride, and placebo. 
The improvement in the placebo group was 
from 2.4 to 2.1 voids/night; improvements in 
the other groups were: terazosin 2.4 to 1.8, 
finasteride 2.5 to 2.1 and the combined 
therapy 2.4 to 2.0 voids/night. The authors 
arbitrarily designated a 50% reduction in 
nocturia as being a meaningful benefit, and 
this was statistically significant for comparing 
response rates by treatment arm (chi-square 
analysis), but the reality is that there was only 
a 17% greater improvement for the 
 
α
 
-blocker 
over placebo in this parameter.
Antimuscarinic therapy for OAB has also 
been explored as a treatment approach for 
nocturia. As nocturia is commonly seen in 
OAB, it has been assumed that first-line 
medications for OAB will exert a clinically 
significant effect. Yet, as antimuscarinics 
exert no effect on 
NP, these agents 
would be expected 
to exert an effect on 
nocturia only 
if the episodes of 
nocturia awakening 
were associated with urgency, and even then, 
antimuscarinics decrease urgency episodes by 
half at best. This suggests that antimuscarinic 
therapy may be ineffective except for the 
group of patients with very severe urgency in 
whom most voids (counting urgency 
incontinence episodes as voids) were 
associated with urgency.
In a representative study, Brubaker and 
Fitzgerald [49] reported on the effect of 
solifenacin on male and female patients with 
OAB using pooled data from four 3-month 
phase III trials. Of the 3032 patients who were 
randomized, 2534 reported nocturia at 
baseline and 62% of the patients reporting 
nocturia were classified as having NP. The 
baseline number of nocturnal episodes was 
higher in those patients with NP 2.27–2.33 vs 
1.66–1.70 voids/night. In those without NP 
there was a ‘significant’ reduction in nocturia 
which amounted only to a numeric difference 
of 0.18 net advantage over placebo for the 
5 mg dose and 0.08 for the 10 mg dose. For 
those patients with NP, the reductions were 
not significantly different from placebo (0.72 
and 0.68 voids/night for the 5 and 10 mg 
doses respectively, vs 0.64 voids/night for 
placebo).
Using trospium chloride, Rudy 
 
et al
 
. [65] 
showed a statistically significant decrease in 
the mean number of nocturic episodes per 
night (baseline 2) of 0.57 voids/night for drug 
vs 0.29 voids/night for placebo, a difference 
of 0.28 episodes. Zinner 
 
et al
 
. [66] reported 
similar results with the same drug.
There has been a group of studies done 
with tolterodine and with the newer agent, 
fesoterodine, which seem to characterize 
the spectrum of results seen with 
the antimuscarinic agents (Table 5) 
[67–70].
Rackley 
 
et al
 
. [50] reported on the median 
percentage reduction in nocturnal voiding 
frequency with tolterodine, dividing the 
nocturnal voids into non-OAB voids, OAB 
voids, and severe OAB voids. Overall, there 
was no significant effect over placebo on 
nocturic episodes, a finding also reported by 
Nitti 
 
et al
 
. [71]. However, with night-time 
dosing, there was a statistically significant 
improvement in OAB-related nocturnal voids 
(those associated with urgency). Such results 
argue for proof of concept for reduction in 
urgency episodes with antimuscarinic agents 
and, further, suggest that antimuscarinics 
potentially offer the most benefit to patients 
with significant and severe frequent 
nocturnal urgency without NP, an opinion 
shared by Brubaker and Fitzgerald [49].
There has been little success in treating 
nocturia with 5
 
α
 
-reductase inhibitor (5ARI) 
agents given to patients for relief of 
symptoms due to BOO caused by prostatic 
enlargement. There have been occasional 
reports of statistically significant results from 
placebo-controlled trials with 
 
α
 
-adrenergic 
blockade, but these results are of doubtful 
clinical significance. The same can be said for 
combined therapy with these two types of 
agents. Statistical success has been achieved 
in some groups with various antimuscarinic 
agents, but, again, the clinical significance 
of these changes in the groups studied 
is doubtful. Hypothetically, to observe a 
clinically significant result with any of these 
agents, one would have to select a group of 
patients with a lot of nocturia episodes, most 
of which were due to DO-related urgency. 
These agents are likely to continue playing 
a role in reducing symptoms of patients 
with LUTS attributable to BOO and to OAB. 
 
‘Antimuscarinic therapy for OAB has also been 
explored as a treatment approach for nocturia’
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However, other types of therapy will need to 
be used to achieve a clinically significant 
reduction in nocturia.
 
Timed diuretic therapy
Diuretics are often prescribed for peripheral 
oedema with no particular attention to 
the time of day at which they would be 
most effective. In patients with NP 
owing to reabsorption of third-space 
lower extremity fluid during recumbency 
associated with intended sleep, diuretics 
should be administered during the mid-
afternoon to address fluid accumulated 
over the course of the day, but not so late as 
to actually exacerbate NP [72,73]. Diuretics 
(specifically bumetanide and furosemide) 
have been conferred Level 2 evidence, Grade 
C recommendation by the Committee for 
Establishment of the Clinical Guidelines for 
Nocturia of the Neurogenic Bladder Society 
[74].
Antidiuretic therapy
For patients whose nocturia is related to 
NP, either alone or combined with OAB or 
BPH, treatment that reduces nocturnal urine 
volumes may be warranted [75]. Assuming 
that patients have been given advice 
regarding night-time fluid intake, and 
other causes of NP have been excluded, then 
antidiuretic therapy may be an appropriate 
choice as it can address insufficient secretion 
of AVP, which results in NP and, frequently, 
nocturia.
Antidiuretic therapy with the synthetic 
analogue of AVP, desmopressin, is the only 
pharmacological therapy which in some 
countries is indicated specifically for nocturia. 
Desmopressin is a selective V2 receptor 
agonist, and therefore has a greater 
specificity of action than AVP, avoiding 
unwanted vasopressor and uterotonic 
effects associated with V1 agonism [76]. 
Desmopressin has a more powerful and 
longer-lasting antidiuretic action than 
AVP. It increases reabsorption of water 
in the distal and collecting tubules of the 
kidney via its action on the V2 receptor, 
and concentrates the urine, decreasing urine 
production, and postponing the need to void 
(Fig. 2).
Given the specific antidiuretic action of 
desmopressin, it is the pharmacological 
therapy of choice for patients with nocturia 
where NP is present, and has a grade A level 1 
recommendation from the International 
Consultation on Incontinence [77]. It 
has a fast onset of action, with urine 
production decreasing within 30 min of oral 
administration [78], and can be administered 
as a tablet or oral lyophilisate (‘melt’) 
formulation requiring no concomitant fluid 
intake. The oral lyophilisate formulation 
has greater bioavailability than the tablet, 
allowing lower dosing to achieve equivalent 
antidiuresis and a well-defined duration of 
action with different dosages in children with 
bedwetting [79].
Several randomized placebo-controlled trials 
have shown the efficacy of oral desmopressin 
in the treatment of adults with nocturia. A 
series of 3-week, randomized, double-blind, 
placebo-controlled trials showed that oral 
desmopressin (0.1, 0.2 or 0.4 mg tablet) is 
effective in both men and women aged ≥18 
years with nocturia. In these studies, clinical 
response was defined as ≥50% reduction in 
nocturnal voids from baseline. In the study of 
men, 34% of patients had a clinical response 
with desmopressin, as compared with 3% 
of patients receiving placebo (P < 0.001) 
[80]; the mean number of nocturnal voids 
TABLE 5 Collected results of recent studies with data for effect of fesoterodine on nocturia
References Treatment Median % decrease, P
Mean decrease in no. voids 
per night/baseline, P
Chapple et al. 2005 [67] Placebo 27 0.32/1.8
Tolterodine extended release 4 mg 25, NS 0.40/2.0, NS
Fesoterodine 4 mg 29, NS 0.39/1.9, NS
Fesoterodine 8 mg 24, NS 0.39/2.0, NS
Nitti et al. 2007 [68] Placebo 25 0.39/2.0
Fesoterodine 4 mg 33, 0.13 0.58/2.2, 0.42
Fesoterodine 8 mg 25, NS 0.55/1.9, 0.09
Herschorn et al. 2010 [69] Placebo 25 0.5/2.3
Tolterodine extended release 4 mg 28, NS 0.6/2.2, NS
Fesoterodine 8 mg 29, NS 0.6/2.2, NS
Dmochowski et al. 2010 
[70]
Placebo no difference in mean ?/2.7
Fesoterodine (titrated 4–8 mg) nocturnal voids or nocturnal urgency 
episodes for either
?/2.6
NS, not statistically significant.
FIG. 2. As the level of plasma vasopressin rises, urine 
osmolarity increases sharply which, in turn, rapidly 
reduces the flow of urine and the need to void.
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reduced from 3.0 to 1.7 and from 3.2 to 2.7 
respectively (P < 0.001). In women results 
were similar: 46% of desmopressin-treated 
women had a clinical response, compared 
with 7% of those on placebo (P < 0.001) [81]; 
the mean number of nocturnal voids was 
reduced from 2.92 to 1.61 and from 2.91 to 
2.36 respectively (P < 0.001). In an additional 
study investigating both men and women, 
33% of desmopressin-treated patients had a 
clinical response, vs 11% with placebo (P < 
0.001), with the mean number of nocturnal 
voids decreasing from 3.26 to 2.01 with 
desmopressin and from 2.8 to 2.42 with 
placebo (P < 0.001) [76]. Long-term studies 
show that efficacy is maintained and 
improved during 10–12 months of treatment; 
a rebound effect is seen when treatment is 
withdrawn, confirming the association 
between continued treatment and response 
[81].
Desmopressin was well tolerated in all studies 
and treatment-related adverse event rates 
were similar to placebo during the double-
blind phases. Hyponatraemia is the only 
potentially serious adverse event associated 
with desmopressin use. Cases are rare and the 
primary predictor is increasing age. Initiation 
of desmopressin is therefore currently not 
indicated for patients aged ≥65 years. The 
mechanisms behind desmopressin-induced 
hyponatraemia are well understood, and 
serum sodium monitoring at baseline and 
early in treatment in older patients can 
greatly reduce their risk of developing the 
condition.
Patients’ initial sleep period is significantly 
prolonged with desmopressin therapy, 
meaning that important slow-wave sleep 
(SWS) in the first part of the night is less likely 
to be interrupted [76]. Van Kerrebroeck 
et al. [76] found that desmopressin-treated 
patients were significantly more likely to 
report that they felt fresh in the morning 
than patients 
receiving placebo 
(P = 0.02). 
Furthermore, the 
proportion of 
patients who 
reported nocturia as 
their most bothersome symptom decreased 
by >50% with long-term desmopressin 
treatment [82].
Most patients diagnosed with BPH or OAB 
have comorbid NP. As previously noted, 
nocturia is resistant to treatment with α1-
blockers and/or anticholinergics. It is 
important, therefore, FVCs are used wherever 
possible and early in the diagnostic process to 
gain a full insight into the causes of nocturia 
in each patient. Appropriate treatment 
selection, designed to address each 
underlying factor at the outset, is then 
possible. It is also important that clinicians 
take time to verify whether patients who have 
been prescribed traditional BPH and OAB 
therapies for daytime LUTS have an 
improvement in their nocturia. If not, 
combined therapy using α1-adrenergic 
blockers and/or anticholinergics in 
conjunction with desmopressin should be 
considered.
Combined therapy is an emerging standard 
in the field of urology, and is becoming 
recognised for its potential to improve 
patient outcomes. Clinical progression 
and IPSSs in patients with BPH are reported 
to be reduced in those receiving concomitant 
5ARI and α1-blocker therapy as compared 
with those receiving monotherapy [83,84]. 
Combined anticholinergic and α1-blocker 
therapy has also been shown to be better than 
monotherapy in men with BPH and OAB [85]. 
The use of combined therapy to address 
multiple factors underlying LUTS as well as 
nocturia is therefore accepted as a rational 
treatment strategy.
Surgical options
Nocturia is the least specific symptom of 
BPH and is the least responsive symptom 
for therapies directed at alleviating 
prostatic obstructions [86]. Nonetheless, 
outlet procedures, including minimally 
invasive procedures for the prostate, 
TURP, and open prostatectomy, are 
offered to address this symptom of 
BPH. Unfortunately, the absence of double 
blind placebo-controlled trials to gauge the 
effects of prostatectomy has limited the 
ability to assess its efficacy in relieving 
nocturia [87].
It is also difficult to identify predictive metrics 
for TURP and other interventions because of 
the documented poor correlation between 
objective and subjective measures in patients 
with obstructing BPH [88]. Studies reviewing 
the effect of prostatectomy on IPSSs focus on 
question seven when evaluating nocturia: 
‘during the last month, how many times did 
‘Most patients diagnosed with BPH or OAB 
have comorbid NP’
©  2 0 11  T H E  A U T H O R S
B J U  I N T E R N A T I O N A L  ©  2 0 11  B J U  I N T E R N A T I O N A L 1 7
E V A L U A T I O N  A N D  T R E A T M E N T  O F  N O C T U R I A
you most typically get up to urinate from the 
time you went to bed at night until the time 
you got up in the morning’? Although this 
question helps quantify nocturia, it does 
not measure the effect of nocturia on a 
patient’s HRQL. In addition, patient age has 
a positive correlation with the IPSSs after 
TURP, with respect to nocturia, although 
age does not correlate with other score 
symptoms [89].
TURP appears to confer a greater 
improvement in BPH symptoms than either 
transurethral microwave thermotherapy 
(TUMT) or oral α-blocker therapy [87]. 
Antunes et al. [90] reported a 1.3 decrease in 
mean nocturia episodes after TURP, while van 
Dijk et al. [87] reported that the outlet 
procedure reduced nocturia by a mean of 
23%. Improvement in symptoms after TURP, 
including nocturia, has been attributed to a 
reduction in DO with relief of the prostatic 
obstruction in addition to the effect of 
removing the adenoma on the detrusor 
muscle [91]. Margel et al. [91] commented 
that postvoid residual urine reduction will 
lead to increased nocturnal bladder filling 
time and a reduction in nocturia. Yoshimura 
et al. [92] reported a 19.2% reduction in 
nocturia after TURP, with an average of 1 
point reduction for nocturia in the IPSS. 
However, they noted that this was the lowest 
degree of improvement among the seven IPSS 
individual symptom scores measured.
Interestingly, Antunes et al. [90] reported that 
the positive effects of TURP on nocturia were 
not correlated with the amount of resected 
tissue. Resection of <30% of prostate tissue 
was enough to alleviate LUTs associated with 
BPH. van Dijk et al. [87] showed that TUMT in 
patients with obstruction reduced nocturia 
episodes by 32% at 6–12 months after 
treatment compared with before treatment 
episodes, and improved patients’ HRQL. 
An older study by Schatzl et al. [93] also 
showed reductions in nocturia in men 
treated with transurethral needle ablation, 
transrectal high-intensity focused ultrasound, 
and transurethral electrosurgical 
vaporization, although patient numbers 
were small.
Despite the lack of absolute metrics, TURP 
and/or laser ablation of the prostate are 
reasonable treatment options for men with 
prostatic obstruction and nocturia, as both 
conditions typically improve in most properly 
selected patients.
CONCLUSIONS
Education of community-based physicians
The authors recognise that healthcare 
providers in multiple specialties may be called 
upon to evaluate and treat patients bothered 
by nocturia. The present article attempts to 
begin the process of broadening the 
understanding of the underpinnings and 
effective treatment strategies for nocturia, 
but they are only a start. Continuing medical 
education regarding nocturia should be 
promoted by teams of experts lecturing on 
the subject in primary through tertiary 
centres in the format of traditional grand 
rounds, as well as dissemination of online 
materials available on commercial websites, 
Wiki articles, and websites maintained by 
academic centres.
Nocturia symposia have been readily available 
at urological meetings worldwide, e.g. those 
of the AUA (and its section meetings), ICS, 
Society for Urodynamics and Female Urology, 
International Urogynecological Society, and 
European Association of Urology. These 
symposia may be made available online in the 
form of webcasts that need not be viewed 
live. In the case of uropharmaceuticals 
approved for nocturia (none currently have a 
specific nocturia indication in the USA), 
package inserts could be designed effectively 
for counselling both physicians and patients 
as to optimal use of these drugs, much as in 
the case for medications with complex 
applications (a fine example being 
intraurethral alprostadil for 
phosphodiesterase 5 refractory erectile 
dysfunction) as well as on the need 
for follow-up (e.g. package inserts 
accompanying sodium cellulose 
phosphate for patients with absorptive 
hypercalciuria).
Clinical recommendations
Participants in the interdisciplinary 
conference on nocturia agreed on the 
following recommendations for the 
evaluation and treatment of patients with 
nocturia:
1. Nocturia is a highly multi-factorial 
condition that can exert a range of deleterious 
effects on health and HRQL.
2. Rather than being viewed simply as a 
secondary symptom of other conditions, 
nocturia should be recognised as a condition 
in its own right with potentially profound 
consequences for health, well-being, 
longevity, and functioning.
3. FVCs are the most useful initial diagnostic 
tools for evaluating nocturia and should be 
used wherever possible, and early in the 
diagnostic process, to most accurately 
characterise the causes of nocturia in each 
patient.
4. Herbal supplements, such as saw palmetto 
berry extract, have not been well studied 
and, while potentially helpful in some 
individuals, cannot be recommended at 
this time.
5. Treatment of nocturia with α1-blockers 
and/or anticholinergics is not generally 
effective. Although statistically significant 
improvements in symptoms have been 
reported, the clinical significance of the 
reported changes is debatable.
6. Timed diuretics given at mid-afternoon 
may be effective in patients with third spacing 
as an aetiology for nocturia.
7. Antidiuretic therapy (e.g. desmopressin) 
has proven well-tolerated and effective in 
several randomized, placebo-controlled trials 
and is recommended as a first-line treatment 
(either as monotherapy or in combination 
with other agents) for patients who have been 
appropriately evaluated and whose nocturia is 
related to NP whether or not accompanied by 
BPH or OAB.
8. Surgical options to remove or reduce 
prostatic or urethral obstructions may help 
alleviate nocturia symptoms. TURP and/or 
laser ablation of the prostate are reasonable 
treatment options for men with prostatic 
obstruction and nocturia.
Future research needs
Although there is a rising awareness of its 
existence, nocturia remains under-studied. 
Conference attendees identified the following 
areas in need of further research:
• Validation and clarification of the 
definition of nocturia in regards to the clinical 
relevance of the ICS definition as well as a 
clearer articulation of the reasons for any 
night-time awakenings [3].
• Basic research into age-related circadian 
rhythms, the effects of ‘near nocturia’ 
(nocturnal arousals owing to the sensation of 
needing to pass urine, followed by sleep 
without voiding) on sleep quality, and the 
relationship between nocturia and restorative 
stages of sleep (e.g. SWS) [94]
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• Research into the question of why patients 
awaken at night and whether, upon such 
awakenings, they void with little or no urge.
• Research to determine the extent to 
which nocturia interferes with objectively 
(polysomnographically) assessed sleep 
duration and sleep continuity, with particular 
emphasis on the duration of sleep before the 
first awakening of the night and the relative 
amount of SWS that occurs during that 
period.
• Epidemiological research into the following 
aspects of nocturia: effect on HRQL, and 
effect on mortality in different age categories, 
genders, and worldwide populations.
• Patient-reported outcomes research into 
the most relevant endpoints to consider in 
research (e.g., number of nocturia episodes, 
nocturia-related impairment in HRQL, 
nocturia-related impairment of sleep 
quality and cognitive function, morbidity, 
mortality)
• Health economics research into the 
true costs of nocturia to society and 
the individual, as well as the impact 
and cost-effectiveness of different 
therapeutic strategies at both patient 
and systems levels.
• Outcomes of therapy for nocturia (e.g. 
behavioural, timed diuretics, timed 
antidiuretics, antimuscarinics, continuous 
positive airway pressure for sleep apnoea, 
combined therapies).
• Research into whether antidiuretic therapy 
should be limited to patients with diary-
confirmed NP and whether antimuscarinic 
therapy is effective in subpopulations of 
patients with significant nocturnal urgency.
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